Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242377 | 0.81 | PIK3CD (0.63) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL245592 | 0.79 | KDM4E (0.49) | PIK3CDPIK3CAKDM4ENPC1PIK3CB | |
| SCHEMBL13019103 | 0.78 | PIK3CD (0.49) | PIK3CDPIK3CAKDM4ENPC1TP53 | |
| SCHEMBL248279 | 0.77 | PIK3CD (0.63) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2713418 | 0.77 | PIK3CD (0.50) | PIK3CDPIK3CAKDM4ENPC1PIK3CB | |
| SCHEMBL2714914 | 0.75 | KDM4E (0.49) | PIK3CDPIK3CAKDM4ENPC1PIK3CB | |
| SCHEMBL3779685 | 0.75 | KDM4E (0.49) | PIK3CDPIK3CAKDM4ENPC1PIK3CB | |
| SCHEMBL2712974 | 0.74 | PIK3CD (0.49) | PIK3CDPIK3CAKDM4ENPC1TGFBR1 | |
| SCHEMBL2711501 | 0.74 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2712261 | 0.74 | PIK3CD (0.71) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588473-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 25/4885PIK3CA 26/4885KDM4E 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.